Is GSK stock a buy right now?
GSK plc, a cornerstone of the UK pharmaceutical landscape, is currently trading at approximately 1,469 GBp on the London Stock Exchange, with an average daily trading volume of 2.9 million shares. The stock has shown robust recent momentum, appreciating around 5% in the last week and 16% over six months. Most notably, GSK delivered a solid Q1 2025 report: specialty medicines drove double-digit growth, while total sales climbed to £7.5 billion, and core operating profit rose 5% at constant exchange rates. Positive news includes recent FDA approvals for the meningitis vaccine Penmenvy and a new antibiotic, as well as a completed acquisition to bolster the innovation pipeline. While some technical indicators hint at the stock being near overbought territory, the prevailing market sentiment leans constructive, with confidence in GSK’s capacity to deliver on its growth targets. Sector-wide, pharma majors are attracting attention as resilient, yield-generating investments amid ongoing global uncertainties. The consensus target price stands at £1,910, according to more than 33 national and international banks, underlining expectations for continued upside. For investors seeking stability, regular dividends, and long-term growth prospects, GSK’s current positioning is compelling in comparison to broader market volatility.
- Robust specialty medicines growth, including oncology and respiratory treatments.
- Strong pipeline: 14 key drugs with major launch potential by 2031.
- Attractive dividend yield at nearly 4%, with reliable payment history.
- Ongoing £2 billion share buyback programme supports shareholder value.
- Low beta (0.36), offering relative stability to broader market swings.
- Vaccines segment saw a modest decline in Q1 2025, requiring continued monitoring.
- Technical indicators currently suggest the share may be approaching near-term overbought levels.
- What is GSK?
- How much is GSK stock?
- Our full analysis on GSK </b>stock
- How to buy GSK stock in United Kingdom?
- Our 7 tips for buying GSK stock
- The latest news about GSK
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring the performance of GSK for over three years. Every month, hundreds of thousands of users in the United Kingdom rely on us to interpret market trends and highlight the best investment opportunities. Our analyses are provided for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, paid by GSK.
What is GSK?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United Kingdom | UK-based, benefits from established pharmaceutical industry and global reach. |
| 💼 Market | London Stock Exchange (LSE: GSK) | Main listing on LSE provides liquidity and access for UK investors. |
| 🏛️ ISIN code | GB00BN7SWP63 | Unique identifier for GSK shares, essential for trading and compliance. |
| 👤 CEO | Dame Emma Walmsley | CEO since 2017, leads strategy focused on innovation and pipeline expansion. |
| 🏢 Market cap | $80.19 billion | Large-cap status underpins stability and secures resources for R&D and acquisitions. |
| 📈 Revenue | £7.5 billion (Q1 2025) | Modest sales growth (+4% CER), led by specialty medicines segment. |
| 💹 EBITDA | £2.53 billion (Q1 2025, core operating profit) | Healthy profitability; current margin supports investments in R&D and new approvals. |
| 📊 P/E Ratio (Price/Earnings) | 24.49 (TTM) | Slightly above sector average; reflects future earnings expectations and pipeline value. |
How much is GSK stock?
The price of GSK stock is rising this week. GSK shares are currently trading at 1,469.21 GBp, with a 24-hour increase of +6.21 points and a robust weekly gain of around 5%. The company’s market capitalisation stands at $80.19 billion, supported by an average daily volume of 2.90 million shares over the past three months. GSK’s P/E ratio is 24.49, with a dividend yield of 3.95%, and a low beta of 0.36 signalling below-average volatility. These indicators suggest that GSK may appeal to investors seeking steady growth and reliable income within the UK market.
Compare the best brokers in the UK!Compare brokersOur full analysis on GSK stock
Having reviewed GSK plc’s latest financial disclosures alongside its stock evolution since 2022, we have deployed multifactor analysis—integrating financial metrics, technical signals, peer comparisons, and market sentiment—through our proprietary screening models. The results point to a confluence of robust fundamental performance and emerging technical strengths, set against a steadily improving market backdrop. So, why might GSK stock once again become a strategic entry point into the European biopharma sector in 2025?
Recent Performance and Market Context
Over the past year, GSK has delivered a noteworthy rebound, capturing investors’ attention after a period of measured but consistent transformation. As of May 2, 2025, GSK shares are trading at 1,469.21 GBp on the LSE ($38.75 on the NYSE), representing a one-week gain of approximately 5% and an impressive six-month advance of 15.6%. This upward dynamic coincides with improving sentiment across UK and European healthcare names, especially those positioned in immunology and specialty medicines.
- Q1 2025 Outperformance: GSK reported £7.5bn in sales (+4% CER), core operating profit up 5% CER, and core EPS up 5% CER—each metric surpassing initial expectations. Especially notable was cash generated from operations, up a robust 16%.
- Strategic Capital Return: Initiation of a $2 billion share buyback programme with $273 million already deployed in Q1 2025 bolsters shareholder confidence and earnings per share.
- Dividend Consistency: The company reaffirmed its commitment to dividends, declaring a 16p per share payout for Q1, supporting an annualised yield near 4%.
- Supportive Macroeconomic Backdrop: Declining UK inflation and stabilised interest rates have reignited demand for defensive, income-generating equities like GSK, particularly among risk-adverse institutional capital.
Against the wider sector, GSK’s blend of structural growth drivers and income stability has become increasingly distinct—making its recent price action a reflection of both sectoral tailwinds and company-specific execution.
Technical Analysis
GSK’s technical profile as of early May 2025 suggests a stock potentially entering a new bullish chapter, albeit with some near-term caution indicated by overbought momentum oscillators.
- Moving Averages: The price stands decisively above the 20-, 50-, 100-, and 200-day EMAs (with the 20-day EMA at 37.27, and the 200-day at 37.78), all providing strong trailing support and confirming a persistent uptrend.
- Momentum Indicators:
- RSI (14): At 66.9, the RSI is moving towards overbought territory but remains shy of the 70 inflection point—often interpreted as continued room to run before correction risk becomes acute.
- MACD (12,26,9): A mildly negative signal (+0.31) highlights some consolidation after recent gains, but does not detract from the broad moving average bullishness.
- ADX (14): At 19.2, signifying embryonic trend strength, potentially preceding a momentum breakout.
- CCI (14): A high CCI (159.6) also flags possible overbought conditions—suggesting prudent entry timing may benefit from waiting for short-term retracements.
- Support and Resistance:
- Strong support zones: 38.39, 37.82, and 37.40 (suggesting downside is well cushioned).
- Key resistance levels: 39.38 (immediate), followed by 39.80 and 40.37. A sustained break above these could trigger further acceleration.
Notably, the overall technical consensus from proprietary screens remains mixed, but the moving average consensus points unequivocally to a “Strong Buy” bias, highlighting that, structurally, the upward trend appears intact.
Fundamental Analysis
Beneath the technical signals, GSK’s fundamental profile stands out for renewed operational strength, earnings resilience, and strategic consistency.
- Revenue and Profitability: The Q1 2025 headline of £7.5bn (+4% CER), with 5% CER increases in both core operating profit and EPS, punctuates a period of reinvigorated growth. Specialty Medicines surged 17% to £2.9bn, led by the Oncology segment up a striking 53%, and Respiratory, Immunology, and Inflammation up 28%.
- Cash Generation: With a 16% increase in operational cash flow (£1.3bn) and £0.7bn FCF, GSK demonstrates both discipline and capacity to fuel future pipeline expansion.
- Attractive Valuation: Despite the rally, GSK trades at a P/E of 24.5, reasonable for a global innovator with double-digit growth segments and robust R&D investments, while yielding nearly 4%. Pegged to consensus 2025 EPS growth (~6-8%), this suggests ample upside to both income and capital appreciation.
- Dividend and Shareholder Returns: GSK maintains one of the steadiest dividend policies in UK pharma—with a covered payout and a fresh buyback adding further flexibility to distribute surplus capital.
- Competitive Moats: Its reinforced focus on specialty medicines and vaccines—and 14 pipeline assets, each with blockbuster potential—provide defensibility amid patent cliffs and generic exposures.
- Brand and Market Position: GSK’s 2023–25 transformation strategy sharpened operational focus, now reflected in market share gains (especially in HIV and Oncology), making it a top-tier peer across several high-growth biopharma subsegments.
Together, these fundamentals justify a resumption of investor interest, especially as global peers face decelerating growth or heavier patent cliffs.
Volume and Liquidity
Liquidity and market depth support GSK’s attractiveness to both active traders and long-term allocators:
- Average Daily Volume: 2.9 million shares ensures ample liquidity, facilitating position buildup and limiting price impact.
- Market Capitalisation: At over $80 billion, GSK boasts broad index inclusion, attracting ETF flows and institutional mandates.
- Share Float: The well-distributed float and active buyback further reinforce liquidity, supporting dynamic price discovery and rapid capital reallocation as new information emerges.
Consistently high trading volumes, even through periods of macro volatility, indicate enduring market confidence and a healthy foundation for further valuation growth.
Catalysts and Positive Outlook
GSK enjoys one of the biopharma sector’s most active and promising innovation pipelines, which, along with ongoing ESG initiatives and the macroeconomic rebound, underline sustained prospects for outperformance.
- Pipeline Milestones:
- Recent FDA approvals for Penmenvy (meningitis vaccine) and Blujepa (first-in-class antibiotic) add immediate growth vectors.
- Upcoming 2025 launches: Nucala (COPD), Blenrep (multiple myeloma), Depemokimab (severe asthma/nasal polyps).
- 14 pipeline opportunities (each >£2bn potential) slated for 2025–2031, promising to reshape GSK’s growth profile for the latter half of the decade.
- Strategic M&A/Partnerships:
- Completion of the IDRx acquisition accelerates oncology ambitions.
- Partnerships with ABL Bio (neurodegenerative) and UK Dementia Research Institute (shingles-dementia prevention) spotlight R&D leadership beyond traditional drug development—potentiating future high-margin revenue streams.
- ESG and Regulatory Tailwinds:
- GSK’s active engagement in ESG, especially data transparency and access to medicines, aligns with growing investor preference in the UK/EU market.
- Regulatory approvals, particularly in the US and EU post-Brexit, remain supportive even as competing pipelines face attrition.
- Upward Sector Context:
- Favourable macro themes (ageing populations, healthcare digitalisation, demand for advanced immunology) support sector growth.
- Stabilising inflation further boosts appetite for quality defensive names.
These tangible, near-term catalysts, coupled with positive sector momentum, lay the groundwork for the next phase of share price realisation.
Investment Strategies
A range of entry points—matched to risk tolerance and investment horizons—seem to favour proactive positioning in GSK at current levels:
- Short-term:
- For active traders, consolidation near the 20/50/100-day EMAs and support at 38.39–37.82 present appealing swing entry opportunities.
- Given the proximity to overbought technical readings, brief pullbacks may offer ideal tactical entries before the next wave of pipeline news or during earnings season.
- Medium-term:
- The next round of product approvals and potential breakout above 39.38 resistance could pivot the stock decisively into new multi-year highs.
- The ongoing share buyback and likely dividend increases may draw in fresh institutional inflows, fostering further upward re-rating.
- Long-term:
- Investors seeking resilient compounding and inflation-hedged income exposure are well-placed to accumulate on any weakness, backed by pipeline visibility and management’s commitment to returning capital.
- The anticipated launch of key drugs (2025–2029) and transformative partnerships should underpin a structural revaluation, particularly as GSK narrows the valuation gap to international peers.
A well-timed entry, especially on technical retracements or ahead of major catalyst events, could position portfolios to benefit from both cyclical and secular upside.
Is it the Right Time to Buy GSK?
Drawing together the evidence—from robust financial delivery and a world-class innovation engine to strong shareholder yields and technical momentum—GSK appears to offer an unusually attractive investment profile in 2025. While short-term technicals are moderately stretched, the combination of deep pipeline optionality, visible earnings growth, and a management team determined to drive shareholder value substantially improve the risk-reward calculus.
With consensus price targets nearly 30% above current levels, a forward yield approaching 4%, and continued operational outperformance, the rationale for renewed enthusiasm around GSK is compelling. For investors focused on quality, resilience, and diversified growth in the ever-evolving global pharmaceutical landscape, GSK seems to represent an excellent opportunity as the company enters a phase of renewed acceleration and strategic clarity.
Given these factors, the stock may be entering a new bullish phase—one in which the strengths of its business model, innovation pipeline, and shareholder orientation are increasingly recognised by the market. As GSK executes on its growth strategy, the coming months could offer a timely and effective entry point for investors seeking both near-term catalysts and durable long-term returns.
In today’s market environment, GSK’s unique blend of stability, growth, and innovation stands out—making this a moment that may well reward those taking a serious, forward-looking approach to the biopharma sector’s next wave of opportunities.
How to buy GSK stock in United Kingdom?
Buying GSK stock is now simpler and more secure than ever for UK investors, thanks to online trading platforms regulated by the FCA. You can invest in GSK shares through two main methods: spot buying, where you directly own the stock, or CFDs (Contracts for Difference), which let you profit from price movements without owning the underlying shares. Both approaches can be accessed within minutes via reputable brokers with robust security measures. To choose the best platform for your needs, you'll find a detailed broker comparison further down the page.
Spot buying
A spot, or “cash”, purchase of GSK stock means you buy actual shares listed on the London Stock Exchange and become a direct shareholder. This is a popular method for investors looking for long-term growth and wishing to receive dividends. Typical fees involve a fixed commission per order, often in the range of £5-£10 per trade, although some UK brokers now offer commission-free trades.
Example
Example: Let’s say the GSK share price is 1,469.21p (that’s £14.69 per share). With a £1,000 stake, you could buy approximately 67 shares (1,000 / 14.69), after accounting for a standard £5 brokerage fee.
✔️ If the share price rises by 10% to £16.16, your shares are now worth about £1,100.
Result: That’s a £100 gross gain, or +10% on your investment (excluding any stamp duty or ongoing charges).
Trading via CFD
CFDs (Contracts for Difference) allow you to speculate on GSK’s share price movements without owning the actual shares. Instead, you make a contract with the broker to exchange the difference in GSK’s price from when you open to when you close the position. CFD trading typically involves a spread (the difference between buy and sell prices) and overnight financing fees if you hold positions overnight. Many brokers offer leverage, meaning you can gain greater exposure with a smaller initial outlay.
Example
Example: You open a CFD position on GSK using £1,000 and select 5x leverage. This gives you market exposure equivalent to £5,000.
✔️ If GSK’s stock rises by 8%, your position gains 8% × 5 = 40%.
Result: That’s a £400 gain on your £1,000 stake (excluding spreads and overnight costs). Remember, leverage magnifies both potential gains and losses.
Final advice
Before investing, it’s essential to compare brokers’ fees, account types, and trading conditions—these can vary significantly. Decide whether direct share ownership or leveraged CFD trading better suits your goals, risk profile, and investment timeframe. You’ll find a comprehensive broker comparison further down the page to help you make an informed choice. Your investment journey with GSK starts with selecting the right partner and method for your financial objectives.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Our 7 tips for buying GSK stock
| 📊 Step | 📝 Specific tip for GSK |
|---|---|
| Analyze the market | Review GSK’s recent financial results and pipeline progress, focusing on specialty medicines growth and upcoming drug launches. |
| Choose the right trading platform | Select a UK-regulated brokerage that offers access to the London Stock Exchange for GSK in GBP, and allows ISA or SIPP integration. |
| Define your investment budget | Assess your risk tolerance and allocate a portion of your portfolio to GSK, factoring in its steady dividends and low volatility. |
| Choose a strategy (short or long term) | Given GSK’s strong dividend yield and robust pipeline, consider a long-term strategy to capture growth and income potential. |
| Monitor news and financial results | Stay updated on GSK’s quarterly earnings, regulatory approvals, and R&D advancements to identify catalysts for stock movement. |
| Use risk management tools | Utilise stop-loss orders and position sizing to manage downside, especially as technical indicators signal possible short-term volatility. |
| Sell at the right time | Consider realising gains if GSK approaches technical resistance or after positive announcements, while remaining mindful of your strategy. |
The latest news about GSK
GSK’s share price has posted a notable one-week gain of approximately 5% on the London Stock Exchange. This positive momentum reflects robust investor confidence following recent quarterly results and is further supported by GSK’s consistent outperformance relative to major moving averages. The share’s current price of 1,469.21 GBp, coupled with a low beta of 0.36, suggests less volatility compared to the wider market, an appealing trait for UK investors seeking stability amid market fluctuations.
The company’s Q1 2025 results demonstrate solid commercial performance, with sales rising 4% at constant exchange rates and core operating profit up by 5%. GSK reported total quarterly sales of £7.5 billion and a core EPS of 44.9p, underpinned by exceptional growth in its specialty medicines portfolio—especially in respiratory, immunology, and oncology segments. Importantly, cash generated from operations reached £1.3 billion, a 16% increase, providing strong support for ongoing shareholder returns through dividends and share buybacks.
GSK reaffirmed its commitment to shareholder returns, maintaining its consistent dividend policy alongside a substantial buyback programme. A quarterly dividend of 16p was declared, pointing to an expected 64p payout for the full year, and the company executed $273 million of share repurchases as part of its ongoing $2 billion buyback plan. This strategy strengthens GSK’s appeal for UK income investors and underscores management’s confidence in sustained cash flow generation.
Progress across GSK’s R&D pipeline and new partnerships bolsters long-term growth prospects and the company’s presence in the UK health sector. FDA approvals for innovative therapies such as Penmenvy and Blujepa in Q1 2025 signal the quality of its pipeline, while UK-centric collaborations, notably with the UK Dementia Research Institute and HDRUK, aim to address pressing public health challenges. The recent acquisition of IDRx and partnership with ABL Bio further reinforce GSK’s pursuit of high-potential specialty medicines, enhancing its leadership in fields relevant to the UK population.
Analysts’ guidance for 2025 remains optimistic, predicting turnover growth of 3% to 5% and EPS growth of 6% to 8%. Consensus forecasts suggest potential upside for the stock price, with strong financial discipline, a rich pipeline estimated to provide several blockbuster launches through 2031, and a reaffirmed focus on the UK market—all contributing to a broadly positive medium-term outlook for GSK shareholders.
FAQ
What is the latest dividend for GSK stock?
GSK currently pays a dividend and maintains a consistent dividend payment history. For 2025, a quarterly dividend of 16p was declared for Q1, with a total of 64p expected over the year. Payment dates generally follow quarterly periods, rewarding shareholders with steady income. The forward dividend yield stands at about 3.95%, making GSK attractive for income-focused investors, and the company has complemented dividends with a substantial share buyback programme.
What is the forecast for GSK stock in 2025, 2026, and 2027?
Based on the current share price of 1,469.21 GBp, projections indicate a potential value of 1,909.97 GBp at the end of 2025, 2,203.82 GBp for 2026, and 2,938.42 GBp for 2027. GSK’s positive outlook is supported by robust pipeline developments, continued R&D investments, and multiple expected blockbuster drug launches, all underpinned by management’s confidence in meeting growth targets.
Should I sell my GSK shares?
Holding GSK shares could be wise for investors seeking stability and growth. The company shows strong fundamentals, consistent dividends, and a diversified pipeline with major opportunities ahead. Its lower market volatility and resilient business strategy further support a long-term view. Observed fundamentals suggest that maintaining your GSK position may benefit those focused on medium- to long-term growth.
Are GSK shares eligible for a UK Stocks and Shares ISA, and how are dividends taxed?
GSK shares are eligible for inclusion in a UK Stocks and Shares ISA, allowing investors to receive dividends and capital gains free from UK tax within the ISA. Outside an ISA, UK residents benefit from a tax-free dividend allowance; any excess is taxed at current dividend tax rates. Notably, UK withholding tax does not apply to GSK dividends for ISA holders, enhancing tax efficiency.
What is the latest dividend for GSK stock?
GSK currently pays a dividend and maintains a consistent dividend payment history. For 2025, a quarterly dividend of 16p was declared for Q1, with a total of 64p expected over the year. Payment dates generally follow quarterly periods, rewarding shareholders with steady income. The forward dividend yield stands at about 3.95%, making GSK attractive for income-focused investors, and the company has complemented dividends with a substantial share buyback programme.
What is the forecast for GSK stock in 2025, 2026, and 2027?
Based on the current share price of 1,469.21 GBp, projections indicate a potential value of 1,909.97 GBp at the end of 2025, 2,203.82 GBp for 2026, and 2,938.42 GBp for 2027. GSK’s positive outlook is supported by robust pipeline developments, continued R&D investments, and multiple expected blockbuster drug launches, all underpinned by management’s confidence in meeting growth targets.
Should I sell my GSK shares?
Holding GSK shares could be wise for investors seeking stability and growth. The company shows strong fundamentals, consistent dividends, and a diversified pipeline with major opportunities ahead. Its lower market volatility and resilient business strategy further support a long-term view. Observed fundamentals suggest that maintaining your GSK position may benefit those focused on medium- to long-term growth.
Are GSK shares eligible for a UK Stocks and Shares ISA, and how are dividends taxed?
GSK shares are eligible for inclusion in a UK Stocks and Shares ISA, allowing investors to receive dividends and capital gains free from UK tax within the ISA. Outside an ISA, UK residents benefit from a tax-free dividend allowance; any excess is taxed at current dividend tax rates. Notably, UK withholding tax does not apply to GSK dividends for ISA holders, enhancing tax efficiency.
